AI Analysis | Feedback

Here are 1-3 brief analogies to describe Quantum-Si (QSI):

• The Illumina of protein sequencing.
• 10x Genomics for proteins.

AI Analysis | Feedback

• Platinum™ Protein Sequencing Instrument: A benchtop instrument designed for next-generation single-molecule protein sequencing.
• Sequencing Consumables: Includes various kits (for sample preparation and sequencing reagents) and specialized sequencing chips necessary for running experiments on the Platinum platform.
• Analysis Software: Software that provides instrument control, data acquisition, and bioinformatics tools for interpreting protein sequencing results.

AI Analysis | Feedback

• Academic and government research institutions
• Pharmaceutical companies
• Biotechnology companies

AI Analysis | Feedback

• GeneCopoeia

AI Analysis | Feedback

Jeff Hawkins, President and Chief Executive Officer

Mr. Hawkins joined Quantum-Si as CEO in October 2022. Prior to this, he served as President and CEO of Truvian Sciences, Inc., where he guided the development of the company's benchtop blood testing system from concept to late-stage development. Before Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina, Inc., where he significantly grew revenue and established market leadership for next-generation sequencing. He has also held roles at GenMark, Hologic, Third Wave Technologies, and Abbott Laboratories. He is a co-inventor on 10 issued or pending patents.

Jeff Keyes, Chief Financial Officer

Mr. Keyes was appointed as Quantum-Si's CFO effective May 15, 2023, bringing over 25 years of experience in senior financial leadership for public and private companies. He previously served as Chief Financial Officer of Spinal Elements, Inc., a private equity-backed medical device company. Before that, he was CFO of Custopharm, Inc., another private equity-backed developer of generic sterile injectable pharmaceuticals, where he contributed to rapid commercial growth and its successful acquisition by Hikma Pharmaceuticals. Mr. Keyes has also held various leadership roles in finance, accounting, and M&A support within life science companies.

Todd Bennett, Chief Commercial Officer

Mr. Bennett joined Quantum-Si as Chief Commercial Officer in September 2024. He possesses over 30 years of commercial leadership experience in the life science tools and diagnostics sectors. His career includes executive leadership and commercial management positions at industry leaders such as Abbott Laboratories, Roche Diagnostics, Immucor, Luminex, Binx Health, and Nuclein.

John Vieceli, PhD, Chief Product Officer

Dr. Vieceli joined Quantum-Si in December 2022 and was named Chief Product Officer in August 2024. He leads Product Development and Operations and has nearly two decades of experience in building technical teams, bringing early-stage technology to market, and leading strategic programs. Prior to Quantum-Si, he held leadership positions at several next-generation DNA sequencing companies, including Illumina, Omniome, and Pacific Biosciences.

Todd Rearick, Chief Technology Officer

Mr. Rearick has served as Quantum-Si's Chief Technology Officer since January 2019. Previously, he was the Chief Technology Officer at Hyperfine Research from January 2018 to January 2019, and a Systems Engineer there from June 2014 to January 2018. Before Hyperfine Research, he was an Engineering Fellow at Life Technologies and a Principal Engineer for Ion Torrent.

AI Analysis | Feedback

The key risks to Quantum-Si's (QSI) business operations are primarily centered around its financial viability, intense market competition, and the potential for shareholder dilution.

1. Continued Financial Losses and High Cash Burn: Quantum-Si is an early-stage life sciences technology company that has consistently reported significant net losses and negative cash flow since its formation in 2013, a trend it expects to continue. For example, the company incurred net losses of $101.0 million, $96.0 million, and $132.4 million in 2024, 2023, and 2022, respectively, and a net loss of $35.7 million in Q3 2025. Its operating cash flow remains significantly negative, and its financial health is characterized by extremely negative margins across various profitability metrics. While a recent capital raise provides a cash runway into Q2 2028, the business model's sustainability is questioned due to its heavy cash burn and lack of profitability, making its stock a high-risk, high-volatility play.
2. Intense Competition and Challenges in Market Adoption: Quantum-Si operates in a dynamic and competitive landscape within the life sciences tools market, vying for market share against companies that often possess greater financial and marketing resources. Key competitors include PacBio, Illumina, Qiagen, Singular Genomics, Element Biosciences, and Nautilus Biotechnology. The company's financial health is heavily dependent on the successful and widespread market adoption of its proprietary protein sequencing technology. However, Quantum-Si faces challenges in scaling its commercial operations and has experienced a slowdown in capital sales, partly due to market-wide spending reductions, particularly in academia, and uncertainty surrounding NIH funding. This has led to lackluster revenue figures, such as $591,000 in Q2 2025 and $552,000 in Q3 2025, highlighting a near-term risk.
3. Risk of Shareholder Dilution and Stock Price Volatility: Quantum-Si faces ongoing risks of dilution for its stockholders due to outstanding warrants and potential future equity issuances necessary to fund its high operating costs and continued development. The exercise of warrants would increase the number of shares eligible for resale in the public market, potentially adversely affecting the stock price. The company's stock has demonstrated high volatility, with a Beta of approximately 2.9, indicating its sensitivity to market movements. Furthermore, Quantum-Si has previously faced non-compliance notices from Nasdaq due to its stock price falling below the minimum bid requirement, though it has since regained compliance. This highlights the inherent instability in its share price.

AI Analysis | Feedback

A clear emerging threat to Quantum-Si (QSI) is the potential for established single-molecule, real-time sequencing companies, particularly Oxford Nanopore Technologies (ONT), to successfully adapt and commercialize their existing technology for comprehensive de novo protein sequencing. ONT already has a robust and widely adopted platform for real-time, single-molecule DNA and RNA sequencing using nanopores. While their primary focus remains nucleic acids, the underlying nanopore technology has significant theoretical and demonstrated potential for direct protein characterization and sequencing. Should ONT leverage its significant R&D capabilities, market presence, and established infrastructure to launch a competitive protein sequencing solution that offers similar or superior accuracy, throughput, and cost-effectiveness to Quantum-Si's Platinum platform, it would represent a direct and potent emerging threat to QSI's core market and technological differentiation.

AI Analysis | Feedback

Quantum-Si (QSI) targets an initial addressable market estimated to be around $8 billion. The broader global proteomics market, in which Quantum-Si's main products and services operate, was estimated at $32.4 billion in 2022 and is projected to reach $72.9 billion by 2028, growing at a compound annual growth rate (CAGR) of 14.6%.

Quantum-Si's main products, such as the Platinum and Platinum Pro instruments and associated consumable kits, are focused on next-generation protein sequencing. The market sizes mentioned are global.

AI Analysis | Feedback

Quantum-Si (QSI) anticipates several key drivers to fuel its revenue growth over the next two to three years:

1. Expansion of Customer Base and Installed Instruments: Quantum-Si is actively focused on increasing its installed base of instruments by offering innovative placement programs and alternative capital acquisition models, such as converting capital expenditures into operating expenses. This strategy aims to reduce financial barriers for research institutions and academic labs, thereby driving long-term market penetration and product validation.
2. Growth in Consumables Revenue: A significant driver of future revenue is the increased sale of high-margin consumables, which directly correlates with the growing utilization of the company's Platinum® platform by its expanding customer base. The company expects increasing consumable sales with every new lab that implements its technology.
3. Launch and Adoption of New Products and Platforms: The introduction of new and enhanced products is crucial for Quantum-Si's growth. This includes the Platinum Pro system, which offers improved workflow and applications, and the transformative Proteus platform, anticipated to launch in the second half of 2026. The Proteus platform is expected to redefine proteomics with increased output, application flexibility, and automation, opening new markets and driving significant revenue. Additionally, the commercial launch of new sequencing kits, such as the version 4 kit, and the upcoming version 3 library preparation kit, are designed to expand proteome coverage, unlock new applications, and lower sample input requirements, further contributing to product sales.
4. Strategic Market Expansion and Partnerships: Quantum-Si aims to broaden its market reach by expanding into new geographical regions and exploring diverse applications for its protein sequencing technology. Strategic partnerships and collaborations, such as the initiative with the Broad Institute, are vital for enhancing market penetration, achieving scientific validation, and strengthening the company's technology offerings.

AI Analysis | Feedback

Share Issuance

• Quantum-Si completed two registered direct offerings in 2025, raising approximately $50 million gross in January and another $50 million gross in July, with net proceeds of about $46.8 million and $46.7 million, respectively.
• A new $100.0 million at-the-market program with Leerink Partners was established on September 26, 2025, for potential future sales of Class A common stock.
• The company went public on September 4, 2020.

Capital Expenditures

• Purchases of property and equipment amounted to $1.634 million for the first six months of 2025 and $2.173 million for the first six months of 2024.
• Capital expenditures are primarily focused on future product development objectives, including the Proteus™ platform, general commercialization, manufacturing development of products, and research and development.
• Historically, cash flows from operations have been negative as the company continues to invest in the development of its technology, with capital expenditures being a primary use of liquidity.